Drug Trial Radar · NCT03528681
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
Last checked: Nov 20, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
270
Actual
Start
May 6, 2021
Primary completion
Sep 15, 2022
Study completion Sep 15, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following 24 or 48 hours of initial ZS therapy (10g TID).
Conditions
- Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate 5gDrug
Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Sodium Zirconium Cyclosilicate 10gDrug
Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
PlaceboDrug
Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Square Mean S-K Level on Days 8-29Time frame: Days 8 to 29 (Randomized treatment study phase) used for model-based least squares mean computation
Locations
66 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Baotou, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Bengbu, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Dalian, China
Research Site
Dongguan, China
Research Site
Fuzhou, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guiyang, China
Research Site
Haikou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Hefei, China
Research Site
Jilin City, China
Research Site
Jinan, China
Research Site
Jingzhou, China
Research Site
Kunming, China
Research Site
Kunming, China
Research Site
Lanzhou, China
Research Site
Nanchang, China
Research Site
Ningbo, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Suzhou, China
Research Site
Taiyuan, China
Research Site
Taiyuan, China
Research Site
Tianjin, China
Research Site
Tianjin, China
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.